Highlights in lymphoma: overview of the 11th International Conference on Malignant Lymphoma
Related Experiment Video
Updated: May 29, 2026

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
Published on: January 9, 2019
Annalisa Chiappella1, Umberto Vitolo
1Hematology II, San Giovanni Battista Hospital and University, Torino, Italy.
The 11th International Conference on Malignant Lymphoma (ICML), the main international forum devoted to basic and clinical research in lymphoid neoplasms, took place in Lugano, Switzerland, from 15 to 18 June 2011. In 2011, 3200 experts in lymphoma from 76 countries attended the meeting. ICML represents the most important forum for the discussion of all aspects relating to basic research, clinical data and results of trials in the treatment of malignant lymphoma worldwide. The incidence of Hodgkin's and non-Hodgkin's lymphoma is increasing. Treatment of lymphoma is heterogeneous, with effective results seen with standard chemotherapy, immunotherapy, high-dose chemotherapy with transplantation and radiotherapy. The biological basis of the growth of lymphoma explains the rationale for the introduction of experimental new drugs in monotherapy or in combination with consolidate schemes. The results have been promising and these issues were discussed during the meeting. On this basis, the ICML report was focused on the most topical, interesting or thought-provoking issues in the treatment of lymphoma.
The 11th International Conference on Malignant Lymphoma (ICML), the main international forum devoted to basic and clinical research in lymphoid neoplasms, took place in Lugano, Switzerland, from 15 to 18 June 2011. In 2011, 3200 experts in lymphoma from 76 countries attended the meeting. ICML represents the most important forum for the discussion of all aspects relating to basic research, clinical data and results of trials in the treatment of malignant lymphoma worldwide. The incidence of Hodgkin's and non-Hodgkin's lymphoma is increasing. Treatment of lymphoma is heterogeneous, with effective results seen with standard chemotherapy, immunotherapy, high-dose chemotherapy with transplantation and radiotherapy. The biological basis of the growth of lymphoma explains the rationale for the introduction of experimental new drugs in monotherapy or in combination with consolidate schemes. The results have been promising and these issues were discussed during the meeting. On this basis, the ICML report was focused on the most topical, interesting or thought-provoking issues in the treatment of lymphoma.
Related Concept Videos
Primary Lymphoid Organs
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
Tumor Immunotherapy
Lymphoid Cells and Tissues
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
Secondary Lymphoid Organs
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
Lymphatic Vessels and Lymph Transport
This one-way system allows fluids, solutes, and even pathogens to enter but prevents their return to the intercellular spaces.
Targeted Cancer Therapies
There are several types of targeted therapies against specific...

